HC Wainwright Boosts Autolus Therapeutics (NASDAQ:AUTL) Price Target to $10.00

Autolus Therapeutics (NASDAQ:AUTL) had its target price hoisted by stock analysts at HC Wainwright from $9.00 to $10.00 in a research report issued on Thursday, MarketBeat reports. The firm currently has a “buy” rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Weiss Ratings raised shares of Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Zacks Research raised shares of Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Jefferies Financial Group raised shares of Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Finally, Truist Financial upgraded shares of Autolus Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Autolus Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $8.75.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.63 on Thursday. The firm’s 50 day moving average is $1.48 and its 200-day moving average is $1.52. The stock has a market capitalization of $433.81 million, a P/E ratio of -1.50 and a beta of 1.93. Autolus Therapeutics has a 12-month low of $1.18 and a 12-month high of $2.70.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.02. The company had revenue of $26.22 million for the quarter, compared to analysts’ expectations of $26.27 million. Autolus Therapeutics had a negative net margin of 311.98% and a negative return on equity of 109.73%. As a group, equities research analysts forecast that Autolus Therapeutics will post -1.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Autolus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Mak Capital One LLC increased its holdings in Autolus Therapeutics by 15.3% in the 4th quarter. Mak Capital One LLC now owns 30,005,343 shares of the company’s stock valued at $59,711,000 after buying an additional 3,987,727 shares during the period. Armistice Capital LLC increased its holdings in Autolus Therapeutics by 12.2% in the 4th quarter. Armistice Capital LLC now owns 17,500,000 shares of the company’s stock valued at $34,825,000 after buying an additional 1,900,000 shares during the period. Schroder Investment Management Group increased its holdings in Autolus Therapeutics by 12.5% in the 4th quarter. Schroder Investment Management Group now owns 9,489,345 shares of the company’s stock valued at $18,694,000 after buying an additional 1,056,092 shares during the period. Bank of America Corp DE increased its holdings in Autolus Therapeutics by 108.1% in the 3rd quarter. Bank of America Corp DE now owns 2,029,593 shares of the company’s stock valued at $3,308,000 after buying an additional 1,054,458 shares during the period. Finally, Atle Fund Management AB increased its holdings in Autolus Therapeutics by 5.8% in the 3rd quarter. Atle Fund Management AB now owns 1,169,634 shares of the company’s stock valued at $1,907,000 after buying an additional 64,173 shares during the period. Institutional investors own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.